{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:10:09Z","timestamp":1790611809764,"version":"4.1.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug\u2013drug interactions. We present a real-world case of long-acting cabotegravir\/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.<\/jats:p>","DOI":"10.1093\/ofid\/ofad604","type":"journal-article","created":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T20:24:22Z","timestamp":1701548662000},"source":"Crossref","is-referenced-by-count":8,"title":["Long-Acting Cabotegravir\/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report"],"prefix":"10.1093","volume":"10","author":[{"given":"Shawnalyn W","family":"Sunagawa","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua P","family":"Havens","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska , USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-0379","authenticated-orcid":false,"given":"Anthony","family":"Podany","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly K","family":"Scarsi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska , USA"},{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H","family":"Bares","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"key":"2023122900461014400_ofad604-B1","article-title":"Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV","author":"Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America"},{"key":"2023122900461014400_ofad604-B2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/cid\/cir230","article-title":"Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculosis meningitis","volume":"52","author":"Torok","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023122900461014400_ofad604-B3","doi-asserted-by":"crossref","first-page":"e00487-17","DOI":"10.1128\/AAC.00487-17","article-title":"Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects","volume":"61","author":"Ford","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023122900461014400_ofad604-B4","article-title":"Cabenuva product label","author":"US Food and Drug Administration"},{"key":"2023122900461014400_ofad604-B5","author":"Heartland National TB Center"},{"key":"2023122900461014400_ofad604-B6","article-title":"Retrovir product label","author":"US Food and Drug Administration"},{"key":"2023122900461014400_ofad604-B7","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/cid\/ciac901","article-title":"Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: a modeling study","volume":"76","author":"Bettonte","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023122900461014400_ofad604-B8","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","article-title":"Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling","volume":"219","author":"Rajoli","year":"2019","journal-title":"J Infect Dis"},{"key":"2023122900461014400_ofad604-B9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","article-title":"Pharmacokinetic and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine","volume":"60","author":"Hodge","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2023122900461014400_ofad604-B10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2023122900461014400_ofad604-B11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3851\/IMP3306","article-title":"Effect of rifabutin on the pharmacokinetics of oral cabotegravir in healthy subjects","volume":"24","author":"Ford","year":"2019","journal-title":"Antivir Ther"},{"key":"2023122900461014400_ofad604-B12","author":"Crauwels"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofad604\/53976216\/ofad604.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad604\/54914486\/ofad604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/10\/12\/ofad604\/54914486\/ofad604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T01:06:53Z","timestamp":1703812013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofad604\/7458072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":12,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofad604","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,12,1]]},"article-number":"ofad604"}}